- Home
- LNKB vs RNAC Comparison
LNKB vs RNAC Comparison
Compare LNKB & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNKB
- RNAC
- Stock Information
- Founded
- LNKB 2018
- RNAC 2007
- Country
- LNKB United States
- RNAC United States
- Employees
- LNKB N/A
- RNAC N/A
- Industry
- LNKB
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- LNKB
- RNAC Health Care
- Exchange
- LNKB Nasdaq
- RNAC Nasdaq
- Market Cap
- LNKB 261.4M
- RNAC 276.3M
- IPO Year
- LNKB N/A
- RNAC 2016
- Fundamental
- Price
- LNKB $6.96
- RNAC $8.19
- Analyst Decision
- LNKB Strong Buy
- RNAC Strong Buy
- Analyst Count
- LNKB 1
- RNAC 4
- Target Price
- LNKB $9.00
- RNAC $40.00
- AVG Volume (30 Days)
- LNKB 110.7K
- RNAC 143.9K
- Earning Date
- LNKB 10-27-2025
- RNAC 11-07-2025
- Dividend Yield
- LNKB 4.29%
- RNAC N/A
- EPS Growth
- LNKB 512.12
- RNAC N/A
- EPS
- LNKB 1.03
- RNAC N/A
- Revenue
- LNKB $122,594,000.00
- RNAC $1,026,000.00
- Revenue This Year
- LNKB $18.26
- RNAC N/A
- Revenue Next Year
- LNKB N/A
- RNAC N/A
- P/E Ratio
- LNKB $6.78
- RNAC N/A
- Revenue Growth
- LNKB 42.32
- RNAC N/A
- 52 Week Low
- LNKB $6.09
- RNAC $7.75
- 52 Week High
- LNKB $7.98
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- LNKB 43.70
- RNAC 35.21
- Support Level
- LNKB $6.85
- RNAC $7.91
- Resistance Level
- LNKB $7.10
- RNAC $9.49
- Average True Range (ATR)
- LNKB 0.19
- RNAC 0.56
- MACD
- LNKB -0.01
- RNAC -0.11
- Stochastic Oscillator
- LNKB 11.32
- RNAC 12.42
About LNKB LINKBANCORP Inc.
Linkbancorp Inc operates in the banking industry. It provides banking services for individuals and businesses such as commercial lending, non-profit banking, treasury management, deposits and loans. Company portfolio segments includes: Agriculture and farmland, Construction, Commercial & industrial, Commercial real estate, Residential real estate, Municipal, customers and Other loans.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.